Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility -- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI)...

InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...